Anti-factor XIIa biologic garadacimab (Andembry) got the FDA greenlight for use in preventing hereditary angioedema (HAE) ...

Early trials found that both garadacimab and sebetralstat were safe when used in patients living with hereditary angioedema, ...

The US Food and Drug Administration (FDA) has approved CSL’s Andembry (garadacimab-gxii) to prevent attacks of hereditary ...

The antibody-based drug Andembry is the first to target factor XIIa, a protein responsible for swelling in people with this ...

Garadacimab-gxii is the first and only treatment that targets factor XIIa (FXIIa) for the prophylactic prevention of ...

A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy ...

Discover a study where findings suggest that previous estimates may have underrepresented the true HAE population by ...

The Food and Drug Administration (FDA) has approved Andembry ® (garadacimab-gxii) for prophylactic use to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years ...

Although Jennifer Namazy, MD, FAAAAI, was first a mentee of Sandra Christiansen, MD, they are now lifelong friends who are ...

Find insight on Hinge Health, Sarepta Therapeutics and more in the latest Market Talks covering Health Care.

Understanding which patients are less likely to respond to first-line therapy may help clinicians arrive at an effective ...

Andembry is the first prophylactic therapy for hereditary angioedema to target factor XIIa, inhibiting the top of the ...